Ra Capital Management LLC Decreased Stake in Tg Therapeutics INC (TGTX) by $10.54 Million as Valuation Declined

Investors sentiment increased to 1.29 in 2019 Q2. Its up 0.21, from 1.08 in 2019Q1. It improved, as 11 investors sold TGTX shares while 27 reduced holdings. 14 funds opened positions while 35 raised stakes. 41.17 million shares or 9.51% less from 45.50 million shares in 2019Q1 were reported. Renaissance Tech Limited reported 160,500 shares. Cubist Systematic Strategies Ltd Co holds 1,300 shares. Susquehanna Int Grp Inc Llp holds 0% or 32,829 shares. 108,324 are owned by Citadel Limited Liability Company. 85,800 were reported by State Of Wisconsin Investment Board. 54,400 were reported by Spark Investment Management Llc. Wells Fargo Mn holds 0% or 56,331 shares in its portfolio. Geode Cap Mngmt Limited Liability Corporation reported 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Georgia-based Voya Inv Mgmt Ltd Liability Co has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Raymond James Financial Services Advsrs stated it has 0.01% in TG Therapeutics, Inc. (NASDAQ:TGTX). Edge Wealth Management Ltd Liability Corp holds 31,420 shares. Point72 Asset Mgmt Lp holds 0.03% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX) for 700,000 shares. Moreover, Fmr Lc has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX). 683 Cap Mngmt Ltd Liability Corp holds 495,000 shares or 0.39% of its portfolio. Pura Vida holds 0.89% or 354,719 shares.

Since June 26, 2019, it had 1 buying transaction, and 0 insider sales for $351,750 activity.

Ra Capital Management Llc decreased its stake in Tg Therapeutics Inc (TGTX) by 16.08% based on its latest 2019Q2 regulatory filing with the SEC. Ra Capital Management Llc sold 1.32 million shares as the company’s stock declined 3.85% . The hedge fund held 6.88 million shares of the health care company at the end of 2019Q2, valued at $59.52M, down from 8.20M at the end of the previous reported quarter. Ra Capital Management Llc who had been investing in Tg Therapeutics Inc for a number of months, seems to be less bullish one the $613.07M market cap company. The stock decreased 4.71% or $0.32 during the last trading session, reaching $6.47. About 991,308 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has declined 31.28% since September 13, 2018 and is downtrending. It has underperformed by 31.28% the S&P500.

Analysts await TG Therapeutics, Inc. (NASDAQ:TGTX) to report earnings on November, 8. They expect $-0.37 EPS, up 13.95 % or $0.06 from last year’s $-0.43 per share. After $-0.42 actual EPS reported by TG Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -11.90 % EPS growth.

More notable recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: Finance.Yahoo.com which released: “Large Option Trader Sells TG Therapeutics Calls After Big Run – Yahoo Finance” on August 12, 2019, also Nasdaq.com with their article: “TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Nasdaq” published on September 12, 2019, Seekingalpha.com published: “TG Therapeutics: Hitting A Growth Inflection – Seeking Alpha” on June 26, 2019. More interesting news about TG Therapeutics, Inc. (NASDAQ:TGTX) were released by: Globenewswire.com and their article: “TG Therapeutics Announces Approximately $85 million in Equity and Debt Financings – GlobeNewswire” published on March 01, 2019 as well as Finance.Yahoo.com‘s news article titled: “Here’s What Hedge Fund Think About TG Therapeutics Inc (TGTX) – Yahoo Finance” with publication date: July 05, 2019.

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.